Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients

Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients

BackgroundTacrolimus, an approved first-line calcineurin inhibitor, is widely prescribed in organ transplantation to prevent allograft rejection. Its narrow therapeutic index requires precise management to achieve optimal dosing and to minimize adverse drug events (ADEs) while ensuring its therapeut...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Tsironi, Konstantinos Lazaros, Effrosyni Mendrinou, Marios Papasotiriou, Stavroula Siamoglou, Kyriaki Kydonopoulou, Anne John, Alexandra Gerou, Spyridon Gerou, Bassam R. Ali, Aristidis G. Vrahatis, George P. Patrinos
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
kidney transplantation
tacrolimus
FK506
C/D ratio
Greek population
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1538432/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1538432/full

Similar Items